Skip to content

Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke

Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke (RICAMIS): a Prospective, Random, Open Label, Blinded End Point, Multi-center Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03740971
Acronym
RICAMIS
Enrollment
1800
Registered
2018-11-14
Start date
2018-12-26
Completion date
2021-04-19
Last updated
2021-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Stroke

Brief summary

The current treatment based on evidence-based medicine for acute ischemic stroke mainly includes reperfusion (intravenous thrombolysis, mechanical thrombolysis), anti-platelet and stroke units. About 1/3 patients can obtain good prognosis through intravenous thrombolysis. Good prognosis can be gotten from about 50 percent of patients with big artery disease by mechanical embolization. However, only a small proportion of the population can be treated with restoration perfusion in the time window. The main purpose of antiplatelet therapy is to prevent the recurrence and progression of stroke, and stroke unit is a kind of management mode. How to improve the neurological function of patients has been a hot and difficult problem in clinical practice. A large number of basic and clinical studies have proved that remote ischemic conditioning (RIC) has protective effect on ischemic stroke. Hahn et al showed that RIC could play a neuroprotective role in cerebral ischemia-reperfusion injury in MCAO model. Other studies have also confirmed that preconditioning RIC has a neuroprotective effect on cerebral ischemia in animal models. One open label study by Hougaard et al shows that RIC can improve the NIHSS score in acute ischemic stroke patients. One recent study found that 300 consecutive days RIC therapy for the patients with symptomatic intracranial atherosclerotic stenosis significantly reduced the recurrence rate of stroke, improved the mRS score and recovered the blood flow in the lesion site. Furthermore, several studies have also shown that RIC can not only improve the neurological function of patients with cerebral infarction after intravenous thrombolysis and mechanical thrombolysis, but also protect the secondary brain injury after carotid stenting. These results suggest that RIC has a neuroprotective effect on ischemic stroke and deserves further study. Based on the above discussion, this study aims to explore the efficacy and safety of RIC in the treatment of acute moderate ischemic stroke.

Interventions

DEVICERemote Ischemic Conditioning treatment

Remote Ischemic Conditioning is given twice a day with 200mmHg pressure.

Guideline-based therapy

Sponsors

General Hospital of Shenyang Military Region
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

1. Patient age ≥18 years; 2. From onset to treatment ≤ 48 hours; 3. Ischemic stroke confirmed by head CT or MRI; 4. 6≤NIHSS score ≤ 16; 5. Premorbid mRS ≤ 1; 6. Signed informed consent.

Exclusion criteria

1. Serious neurological deficits before onset ( mRS ≥ 2); 2. The aetiology of cardiogenic embolism, such as rheumatic mitral or aortic stenosis, artificial heart valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, left ventricular wall thrombus or valve neoplasm, congestive heart failure, bacterial endocarditis, etc; 3. Uncontrolled severe hypertension (Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg after drug treatment); 4. Subclavian artery stenosis ≥ 50% or subclavian steal syndrome; 5. Intracranial tumor, arteriovenous malformation or aneurysm; 6. Severe abnormalities in coagulation; 7. Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.; 8. Comorbidity with any serious diseases and life expectancy is less than half a year; 9. Participating in other clinical trials within 3 months; 10. Patients not suitable for this clinical studies considered by researcher;

Design outcomes

Primary

MeasureTime frame
Proportion of mRS (0-1)90±7 days

Secondary

MeasureTime frameDescription
Proportion of mRS (0-2)90±7 days
Incidence of early neurological deterioration7 daysmore than 4 NIHSS score increase compared with baseline
Incidence of stroke associated pneumonia12±2 days
occurrence of stroke or other vascular events90±7 days
proportion of death of any cause90±7 days

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 11, 2026